Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, SRU Biosystems


Kreatech recently launched its monoclonal anti-cyanine 3 and anti-cyanine 5 antibodies. The company claims that the antibodies are suitable for detection and enhancement of signals from cyanine 3 and cyanine 5 labeled nucleic acids or proteins, and are applicable to microarray experiments, in situ hybridizations, immunohistochemistry, western blotting or flow cytometry.

According to the Dutch biotech, the anti-cyanine 5 antibody can be used to detect Cy5, Dyomics 647 or AlexaFluor 647, bound to proteins or nucleic acid probes. The anti-cyanine 3 antibody can be used to detect Cy3, or Dyomics 547, bound to proteins or nucleic acid probes. Anti-cyanine 3 and anti-cyanine 5 antibodies can be used in single- or dual-color assays.

SRU Biosystems last week launched its BIND System, with its accompanying BIND Reader and BIND Biosensor plates for drug discovery applications.

The life sciences company claims that the system enables label-free detection of biomolecular interactions using proteins, peptides or cells and can provide sensitive measurement of binding on the biosensor surface. SRU recommends the system for use in basic research, drug discovery, development, manufacturing, and QC.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.